Literature DB >> 10080566

Improved cognition in Alzheimer's disease with short-term D-cycloserine treatment.

G E Tsai1, W E Falk, J Gunther, J T Coyle.   

Abstract

OBJECTIVE: Glutamatergic neurotransmission is important for memory and cognition and is severely affected in Alzheimer's disease. D-Cycloserine exhibits partial agonist activity at the glycine site of N-methyl-D-aspartate subtype glutamate receptor, facilitating activation of the receptor and improving cognition and memory.
METHOD: Seventeen patients with Alzheimer's disease received a three-phase, double-blind, placebo-controlled trial of 50 mg and 100 mg/day of D-cycloserine.
RESULTS: D-Cycloserine was associated with significant improvement in scores on the cognitive subscale of the Alzheimer's Disease Assessment Scale (improvement of 3.0 points) when given at a dose of 100 mg/day.
CONCLUSIONS: D-Cycloserine has cognitive benefits for patients with Alzheimer's disease.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10080566     DOI： 10.1176/ajp.156.3.467

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN： 0002-953X            Impact factor:   18.112


  33 in total

Review 1.  Augmentation treatment of psychotherapy for anxiety disorders with D-cycloserine.

Authors:  Stefan G Hofmann; Mark H Pollack; Michael W Otto
Journal:  CNS Drug Rev       Date:  2006 Fall-Winter

2.  A NMDA receptor glycine site partial agonist, GLYX-13, simultaneously enhances LTP and reduces LTD at Schaffer collateral-CA1 synapses in hippocampus.

Authors:  Xiao-lei Zhang; John A Sullivan; Joseph R Moskal; Patric K Stanton
Journal:  Neuropharmacology       Date:  2008-08-29       Impact factor: 5.250

3.  Constitutive activation of the N-methyl-D-aspartate receptor via cleft-spanning disulfide bonds.

Authors:  Marie L Blanke; Antonius M J VanDongen
Journal:  J Biol Chem       Date:  2008-05-01       Impact factor: 5.157

4.  Restoration of synaptic plasticity and learning in young and aged NCAM-deficient mice by enhancing neurotransmission mediated by GluN2A-containing NMDA receptors.

Authors:  Gaga Kochlamazashvili; Olena Bukalo; Oleg Senkov; Benedikt Salmen; Rita Gerardy-Schahn; Andreas K Engel; Melitta Schachner; Alexander Dityatev
Journal:  J Neurosci       Date:  2012-02-15       Impact factor: 6.167

5.  Molecular mechanisms of D-cycloserine in facilitating fear extinction: insights from RNAseq.

Authors:  Stefanie Malan-Müller; Lorren Fairbairn; Willie M U Daniels; Mahjoubeh Jalali Sefid Dashti; Edward J Oakeley; Marc Altorfer; Martin Kidd; Soraya Seedat; Junaid Gamieldien; Sîan Megan Joanna Hemmings
Journal:  Metab Brain Dis       Date:  2015-09-23       Impact factor: 3.584

6.  Amygdaloid zif268 participated in the D-cycloserine facilitation effect on the extinction of conditioned fear.

Authors:  I-Tek Wu; Tso-Hao Tang; Meng-Chang Ko; Chen-Yu Chiu; Kwok-Tung Lu
Journal:  Psychopharmacology (Berl)       Date:  2015-08-19       Impact factor: 4.530

7.  Inhibition of serine palmitoyltransferase reduces Aβ and tau hyperphosphorylation in a murine model: a safe therapeutic strategy for Alzheimer's disease.

Authors:  Hirosha Geekiyanage; Aditi Upadhye; Christina Chan
Journal:  Neurobiol Aging       Date:  2013-03-23       Impact factor: 4.673

Review 8.  The role of the N-methyl-D-aspartate receptor in Alzheimer's disease: therapeutic potential.

Authors:  P Murali Doraiswamy
Journal:  Curr Neurol Neurosci Rep       Date:  2003-09       Impact factor: 5.081

Review 9.  D-cycloserine for Alzheimer's disease.

Authors:  K Laake; A R Oeksengaard
Journal:  Cochrane Database Syst Rev       Date:  2002

Review 10.  Enhancing exposure-based therapy from a translational research perspective.

Authors:  Stefan G Hofmann
Journal:  Behav Res Ther       Date:  2007-06-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.